Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Seattle Children'S Hospital (D/B/A Seattle Children'S Research Institute) currently has 1 pending office action in its patent portfolio. This 1 action is assigned to 1 distinct examiner. YU, DAVID TUYANG is the busiest examiner for the hospital, currently handling 1 pending office action. This examiner is responsible for the only active office action recorded for the portfolio.
The portfolio shows 1 distinct examiner and 0 distinct art units. This indicates that while an examiner is assigned, the specific art unit classification is not recorded in the current data set. With 1 pending office action and 1 distinct examiner, the hospital's current patent office interactions are concentrated. This suggests a focused scope of pending examination activity for the hospital at this time.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| §103 only | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICKOL, GARY B | 1 | 47.1% | +31.1% |
| KUDO, KEN | 1 | — | — |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
| BARRERA, IMMACULADA | 1 | 31.0% | +80.0% |
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560903 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | NICKOL, GARY B | — |
| 18463683 | Processing Images to Associate with Stages of a Surgical Procedure | KUDO, KEN | — |
| 18546199 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | HOWARD, ZACHARY C | — |
| 18044752 | DIAGNOSTIC METHODS FOR KAWASAKI DISEASE | FRITCHMAN, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042448 | SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2 | BARRERA, IMMACULADA | 10d overdue |
| 17998206 | CHIMERIC ANTIGEN RECEPTORS (CARS) TARGETING NATURAL KILLER CELLS | BELYAVSKYI, MICHAIL A | 34d |
| 18560903 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | NICKOL, GARY B | — |
| 18546199 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | HOWARD, ZACHARY C | — |
| 18044752 | DIAGNOSTIC METHODS FOR KAWASAKI DISEASE | FRITCHMAN, REBECCA M | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 2671 | 1 |
| 1674 | 1 |
| 1758 | 1 |
| 1671 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560903 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | NICKOL, GARY B | 1643 | §102§112 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18463683 | Processing Images to Associate with Stages of a Surgical Procedure | KUDO, KEN | 2671 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18546199 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | HOWARD, ZACHARY C | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18044752 | DIAGNOSTIC METHODS FOR KAWASAKI DISEASE | FRITCHMAN, REBECCA M | 1758 | §101§103§112 | Final Rejection | — | Pending | Mar 09, 2023 |
| 18042448 | SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2 | BARRERA, IMMACULADA | 1671 | Other | Non-Final OA | 10d overdue | Pending | Feb 21, 2023 |
| 17998206 | CHIMERIC ANTIGEN RECEPTORS (CARS) TARGETING NATURAL KILLER CELLS | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 34d | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial